Please visit answersincme.com/ZXA860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in interstitial lung disease (ILD) discuss the latest information, including post-congress insights, on advancing patient-centered ILD care with antifibrotics, treatment innovations, and multidisciplinary approaches. Upon completion of this activity, participants should be better able to: Assess recommended antifibrotic treatment for patients with ILDs; Review the rationale for novel therapy for fibrosing ILDs; and Outline multidisciplinary, patient-centered strategies to enhance care for individuals with ILDs.

Please visit answersincme.com/XWB860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in melanoma discusses combination anti–programmed cell death protein 1 (PD-1) plus anti–lymphocyte-activation gene 3 (LAG-3) therapy. Upon completion of this activity, participants should be better able to: Review the latest clinical evidence supporting use of combination anti–PD-1 plus anti-LAG-3 therapy in the first-line setting for patients with unresectable, advanced melanoma; Identify eligible patients with unresectable, advanced melanoma who can benefit from the use of combination anti–PD-1 plus anti–LAG-3 therapy in the first-line setting; and Outline strategies for managing adverse events associated with combination anti–PD-1 plus anti–LAG-3 therapy.

Please visit answersincme.com/ABT860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in neurology discusses the clinical evidence for novel complement (C5) inhibitors in the treatment of generalized myasthenia gravis (gMG) and personalized multidisciplinary management strategies. Upon completion of this activity, participants should be better able to: Review the rationale for novel C5 inhibitors in the treatment of generalized myasthenia gravis (gMG); Describe the long-term clinical data of C5 inhibitors for the treatment of gMG; and Discuss strategies to personalize multidisciplinary management plans for patients with gMG.

Please visit answersincme.com/BFK860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in neurology discusses strategies to optimally incorporate FcRn antagonists into care plans for patients with generalized myasthenia gravis (gMG). Upon completion of this activity, participants should be better able to: Describe the disease burden of generalized myasthenia gravis (gMG); Review the evidence for the use of neonatal fragment crystallizable receptor (FcRn) antagonists in gMG; and Outline strategies to optimally incorporate FcRn antagonists into the care of patients with gMG.

Please visit answersincme.com/SFM860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in family and emergency medicine discuss collaborative strategies for the optimal management of type 2 inflammatory diseases. Upon completion of this activity, participants should be better able to: Specify how type 2 inflammation contributes to the pathophysiology of chronic type 2 inflammatory diseases; Recognize the cardinal signs and symptoms of diseases presenting with type 2 inflammation; Apply treatment considerations for patients with multiple type 2 inflammatory diseases; and Outline strategies for optimizing care coordination for patients with type 2 comorbidities across providers and settings.

Please visit answersincme.com/TSJ860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in pulmonology discusses systemic therapy, including biologics, for the management of moderate to severe asthma. Upon completion of this activity, participants should be better able to: Review recommended management strategies for moderate to severe asthma; Explain the rationale for the use of biologics in the treatment of patients with moderate to severe asthma; Identify patients eligible for systemic therapy for the treatment of moderate to severe asthma; and Outline evidence-based, long-term strategies to improve lung function in patients with moderate to severe asthma.

Please visit answersincme.com/JUC860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in obstetrics and gynecology and a cervical cancer survivor discuss strategies to increase human papillomavirus vaccination uptake, thereby reducing cervical cancer risk. Upon completion of this activity, participants should be better able to: Review guideline-recommended clinical strategies to reduce cervical cancer risk; Outline patient-focused strategies to increase acceptance of HPV vaccination across patient subpopulations; and Identify clinical approaches to enhance the uptake of recommended schedules for HPV vaccination.

Please visit answersincme.com/KSU860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in otolaryngology discuss the role of biologic therapies in chronic rhinosinusitis with nasal polyps (CRSwNP). Upon completion of this activity, participants should be better able to: Recognize considerations for initiating treatment with a biologic therapy in patients with CRSwNP; Review the clinical implications of the latest efficacy and safety data for novel approved biologics in CRSwNP; and Outline strategies to optimize the use of biologics in patients with CRSwNP over the long term.

Please visit answersincme.com/YWD860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in rhinology discusses the use of biologics for the management of chronic rhinosinusitis with nasal polyps (CRSwNP). Upon completion of this activity, participants should be better able to: Identify key considerations for initiating a biologic therapy in patients with CRSwNP; Discuss the clinical impact of the latest data for novel approved biologics in CRSwNP; and Apply best practice approaches for management of biologics in patients with CRSwNP. This activity is intended for US healthcare professionals only.

Please visit answersincme.com/VNG860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in reproductive health discusses the rationale for human papillomavirus (HPV) vaccination in appropriate adults, its clinical impact, and strategies to incorporate HPV vaccination into prevention plans. Upon completion of this activity, participants should be better able to: Recognize the rationale for HPV vaccination in appropriate adults ages 27-45 years old; Review the clinical impact of HPV vaccination in appropriate adults ages 27-45 years old; and Outline patient-centered strategies to appropriately incorporate HPV vaccination into prevention plans for eligible adults ages 27-45 years old.